Trial Profile
A Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission and Prevention of Structural Joint Damage During Treatment With Tocilizumab (TCZ), as a Monotherapy and in Combination With Methotrexate (MTX), Versus Methotrexate in Patients With Early, Moderate to Severe Rheumatoid Arthritis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Dec 2021
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms FUNCTION
- Sponsors Roche
- 07 Feb 2020 Results (n=1750) of post hoc analysis determining if inclusion of patients on background GC use influences efficacy and safety outcomes of RA randomised clinical trials from AMBITION, ACT-RAY, ADACTA and FUNCTION on initiation of tocilizumab (TCZ) or adalimumab (ADA) or methotrexate (MTX) monotherapy. published in the Annals of the Rheumatic Diseases
- 15 Jun 2019 Results assessing prediction of remission with Tocilizumab from ACT-RAY, ADACTA, AMBITION, and FUNCTION trials presented at the 20th Annual Congress of the European League Against Rheumatism
- 24 Oct 2018 Results from the FUNCTION and LITHE studies presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting